Search results for " metabolic"

showing 10 items of 1022 documents

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

EFFETTO DELLO SPORT E DELL'ESERCIZIO FISICO NELLA SINDROME METABOLICA: TERAPIA FARMACOLOGICA E NON FARMACOLOGICA

2010

ATTIVITA' FISICA - SINDROME METABOLICA
researchProduct

Optimized In Silico Modeling of Drug Absorption after Gastric Bypass: The Case of Metformin

2021

Bariatric surgery is an effective treatment for severe obesity and related comorbidities, such as type II diabetes. Gastric bypass surgery shortens the length of the intestine, possibly leading to altered drug absorption. Metformin, a first-line treatment for type II diabetes, has permeability-dependent drug absorption, which may be sensitive to intestinal anatomic changes during bypass surgery, including Roux-en-Y gastric bypass (RYGB). Previous computer simulation data indicate increased metformin absorption after RYGB. In this study, we experimentally determined the region-dependent permeability of metformin, using the rat single-pass intestinal perfusion method (SPIP), which we then imp…

Absorption (pharmacology)obesitymedicine.medical_specialtyRoux-en-Y gastric bypassbariatric surgeryUrologyPharmaceutical Sciencemedicine.disease_causeArticleJejunumGastroPlusTMPharmacy and materia medicaIn vivomedicineGastroPlus<sup>TM</sup>Intestinal permeabilityintestinal permeabilitybusiness.industryGastric bypass surgerynutritional and metabolic diseasesmedicine.diseaseMetforminRS1-441program simulationmedicine.anatomical_structuresegmental-dependent absorptionBypass surgeryDuodenummetforminbusinessmedicine.drugPharmaceutics
researchProduct

Crystallographic, spectroscopic and electrochemical characterization of pyridine adducts of magnesium(II) and zinc(II) porphine complexes

2013

Abstract A new purification method of magnesium(II) and zinc(II) porphine complexes (MgP and ZnP, respectively) by crystallization of their respective pyridine adducts is described. Pure MgP and ZnP can be regenerated by removal of the coordinated pyridine ligands by heating at 200 °C under vacuum. X-ray crystallographic structures of the pyridine adducts are presented for the first time. NMR analyses of the adducts reveal the coordination of two pyridine molecules. Electrochemical as well as UV-vis absorption spectroscopy analyses in DMF of MgP·(Py)2, ZnP·(Py)2, MgP and ZnP indicate that pyridine adducts are totally dissociated. Besides, oxidation peaks of these complexes are totally irrev…

Absorption spectroscopyChemistryMagnesiumGeneral Chemical Engineeringnutritional and metabolic diseaseschemistry.chemical_elementGeneral ChemistryZincNuclear magnetic resonance spectroscopyAdductCrystallographychemistry.chemical_compoundPyridineMoleculeReactivity (chemistry)Comptes Rendus Chimie
researchProduct

IMPROVE-IT: what have we learned?

2016

Purpose of review: Recent studies and dyslipidemia treatment guidelines indicate that combination lipid-lowering therapy is frequently needed and its use has increased in recent years. Ezetimibe and simvastatin as a fixed dose is an efficacious treatment choice based on positive results of the recent IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). In this review, we discuss recent controversies surrounding ezetimibe and provide clinical perspective on the results of the IMPROVE-IT study. Recent findings: IMPROVE-IT is the first trial that demonstrates a significant clinical benefit of a nonstatin hypolipidemic agent (ezetimibe) used in combination with sta…

Acute coronary syndromeSimvastatinHypercholesterolemia030204 cardiovascular system & hematologyPharmacologyFixed dose03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacotherapyEzetimibeMedicineHumansLow-density lipoprotein cholesterol030212 general & internal medicineAcute Coronary SyndromeIMPROVE-IT trialbusiness.industryCholesterolAnticholesteremic AgentsAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseCardiovascular riskEzetimibeTreatment OutcomechemistrySimvastatinAzetidinesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineDyslipidemiamedicine.drugCurrent opinion in cardiology
researchProduct

Incident colorectal cancer in Lynch syndrome is usually not preceded by compromised quality of colonoscopy

2019

AbstractBackground: Lifetime incidence of colorectal cancer (CRC) especially in carriers of MLH1 and MSH2 pathogenic germline variants in mismatch repair genes is high despite ongoing colonoscopy s...

AdenomaAdultMaleOncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHereditary non-polyposis colorectal cancerCOLONOSCOPYColorectal cancersurveillance colonoscopyeducationColonoscopycolorectal cancerMLH1Germline03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistriesneoplasmsFinlandAgedNeoplasm StagingRetrospective Studiesmedicine.diagnostic_testbusiness.industryIncidenceIncidence (epidemiology)LYNCH SYNDROMEGastroenterologynutritional and metabolic diseasesMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposisdigestive system diseasesLynch syndrome3. Good healthMSH2Population Surveillance030220 oncology & carcinogenesis3121 General medicine internal medicine and other clinical medicineFemale030211 gastroenterology & hepatologyDNA mismatch repairColorectal Neoplasmsbusiness
researchProduct

Celiac disease and selective immunoglobulin A deficiency

1997

Selective IgA deficiency was observed in 12 of 688 (1.7%) patients with celiac disease who were clinically undistinguishable from patients with celiac disease with normal IgA levels. This high prevalence of IgA deficiency in patients with celiac disease makes serum IgA assay advisable when screening for celiac disease is performed by measurement of antigliadin antibodies or anti-IgA endomysium antibodies. Similarly, subjects with IgA deficiency should be considered at risk of celiac disease.

AdolescentGlutensCross-sectional studyMuscle Fibers SkeletalDiseaseSelective IgA deficiencyImmunoglobulin EGliadinCoeliac diseaseMyofibrilsRisk FactorsImmunopathologyConfidence IntervalsDiet Protein-RestrictedPrevalencemedicineHumansChildChi-Square Distributionbiologybusiness.industryAge FactorsIgA DeficiencyInfantnutritional and metabolic diseasesmedicine.diseaseEndomysiumdigestive system diseasesImmunoglobulin ACeliac DiseaseIntestinal DiseasesCross-Sectional Studiesmedicine.anatomical_structureImmunoglobulin MChild PreschoolImmunoglobulin GPediatrics Perinatology and Child HealthImmunologybiology.proteinAntibodybusinessFollow-Up StudiesThe Journal of Pediatrics
researchProduct

Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome

2007

Objective To assess message expression of adiponectin and leptin in visceral and SC fat in women with polycystic ovary syndrome (PCOS) and in control women. Design Prospective clinical trial. Setting Academic medical centers in Mexico City, Mexico and New York, New York. Patient(s) Women with PCOS and control women. Intervention(s) Surgical biopsies of visceral (omental) and subcutaneous (SC) adipose tissue, fasting blood samples, and ultrasound measurements of visceral and SC fat. Main Outcome Measure(s) Messenger RNA assessment of adiponectin and leptin in adipose tissue samples; serum measurements of adiponectin, leptin, glucose, insulin, and hormone levels; measurements of fat quantity …

AdultBlood GlucoseLeptinmedicine.medical_specialtymedicine.medical_treatmentAbdominal FatNew YorkSubcutaneous FatAdipokineAdipose tissueBody Mass IndexSettore MED/13 - EndocrinologiaInsulin resistanceInternal medicineAbdominal fat adiponectin leptin polycystic ovary syndrome insulin resistancemedicineHumansInsulinProspective StudiesRNA MessengerMexicoUltrasonographyAdiponectinbusiness.industryLeptinInsulinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryEndocrinologyReproductive MedicineCase-Control StudiesFemaleAdiponectinInsulin ResistancebusinessBody mass indexhormones hormone substitutes and hormone antagonistsPolycystic Ovary Syndrome
researchProduct

Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exe…

2005

Aim: The aim of this study was to investigate the role of skeletal muscle fibre type in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance (IGT) during a 2-year exercise anddietary intervention. Methods: Muscle biopsies (musculus vastus lateralis) were taken from 22 subjects belonging to the intervention group of the Finnish Diabetes Prevention Study [1]. According to their myosin heavy chain (MHC) profile at the baseline, the subjects were divided into two groups: IGT s l o w (n = 10) with a high proportion of MHC I isoforms and IGT f a s t (n = 12) with a high proportion of MHC II isoforms in the vastus lateralis muscle. The intervention con…

AdultBlood GlucoseMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyDiet Reducingendocrine system diseasesVastus lateralis muscleEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalCarbohydrate metabolismImpaired glucose toleranceGlycogen Synthase Kinase 3EndocrinologyInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceWeight LossInternal MedicinemedicineHumansAerobic exerciseObesityMuscle SkeletalGlycogen synthaseExerciseAgedMyosin Heavy Chainsbiologybusiness.industrynutritional and metabolic diseasesSkeletal muscleMiddle Agedmedicine.diseaseCombined Modality Therapymedicine.anatomical_structureEndocrinologybiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsFollow-Up StudiesDiabetes, Obesity and Metabolism
researchProduct

Glycated serum proteins and glucose tolerance

1988

Glycated serum proteins (GSP), stable glycated hemoglobin (HbA1c) together with some metabolic parameters were evaluated in 120 subjects, 30 with normal glucose tolerance (NGT), 30 with impaired glucose tolerance (IGT), 30 with non-insulin-dependent diabetes mellitus (NIDD), and 30 with insulin-dependent diabetes mellitus (IDD). GSP levels were significantly higher in IGT, NIDD and IDD than in NGT. HbA1c levels were not significantly higher in IGT in comparison with NGT, but were significantly higher in NIDD and in IDD than in NGT and IGT. GSP correlated better than HbA1c with all metabolic parameters considered. Taking into account the distribution of the values, GSP showed a smaller overl…

AdultBlood GlucoseMalemedicine.medical_specialtyGlycosylationendocrine system diseasesEndocrinology Diabetes and MetabolismImpaired glucose toleranceHba1c levelchemistry.chemical_compoundEndocrinologystomatognathic systemReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansTriglyceridesGlycated HemoglobinGlucose tolerance testmedicine.diagnostic_testbusiness.industryCholesterolnutritional and metabolic diseasesBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood proteinsCholesterolDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2chemistryHyperglycemiaMetabolic control analysisFemaleGlycated hemoglobinbusinesshormones hormone substitutes and hormone antagonistsActa Diabetologica Latina
researchProduct